NextGen Healthcare Q3 Earnings Beat Consensus, Lifts FY22 Guidance
See more from Benzinga
Valneva Advances Booster Phase Of Its Cov-Compare COVID-19 Vaccine Trial
Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.